Table 3. Cryptosporidium oocytes in mice fecal smears stained with Modified Ziehl-Neelsen (MZN) (x400).
| Group | G1(+ve Control) | G2Low Dose S. arboricola extract | G3High Dose S. arboricola extract | G4NTZ treated | p -value |
|---|---|---|---|---|---|
| Days PI | |||||
| Day 3 | 97.3 ± 3.5a,c | 94.9 ± 5.5qd | 90.1 ± 7.2 cd | 92.6 ± 5.3cd | 0.017* |
| Day 4 | 102.6 ± 4.5a,c | 100.1 ± 5.5qd | 95.7 ± 3.4 cd | 97.3 ± 62cd | 0.016* |
| Day 5 | 107.3 ± 3.7a,c | 104.6 ± 7.5qd | 98.2 ± 6.7 cd | 102.1 ± 7.6cd | 0.014* |
| Day 6 | 117.6 ± 3.91a,b | 113.5 ± 3.5 | 103.8 ± 7.6d | 107.9 ± 6.3 d | 0.033* |
| Day 7 | 98.9 ± 4.6 | 95.7 ± 9.2 | 89.1 ± 6.5a | 91.8 ± 7.6 | 0.031* |
| Day 8 | 90.6 ± 7.6 | 86.7 ± 6.7a | 78.5 ± 63a | 81.9 ± 4.7b,c | 0.022 * |
| Day 9 | 82.0 ± 6.4a | 77.9 ± 7.7a | 67.6 ± 7.4a | 72.3 ± 1.7b,c | 0.007* |
| Day 10 | 74.3 ± 9.1a | 70.8 ± 3.9a | 57.4 ± 9.2a | 64.2 ± 3.9b,c,d | 0.003 * |
| Day 11 | 62.5 ± 5.4a,b | 54.5 ± 7.6a,d | 46.9 ± 9.2,d | 49.8 ± 6.3b,c,d | <0.004* |
| Day 12 | 51.2 ± 6.5a,b,c | 43.1 ± 7.9a,b,d | 35.9 ± 3.9a,c,d | 38.1 ± 5.3b,c,d | <0.002* |
| Day 13 | 42.5 ± 6.6a,b,c | 35.3 ± 5.7a,b,d | 27.2 ± 6.3c,d | 30.5 ± 0.5.8,c,d | <0.001* |
| Day 14 | 33.7 ± 4.3a,b,c | 26.7 ± 6.8a,b,d | 20.1 ± 6.3c,d | 23.2 ± 6.4b,c,d | <0.002* |
| Day 15 | 28.4 ± 4.6a,b,c | 22.1 ± 7.4a,b,d | 15.5 ± 5.4c,d | 18.2 ± 5.7c,d | <0.002* |
| Day 16 | 20.3 ± 3.6a,b,c | 16.3 ± 3.6a,b,d | 9.9 ± 5.2c,d | 12.2 ± 6.1c,d | <0.001* |
| Day 17 | 14.8 ± 2.7a,b,c | 10.8 ± 5.8a,b,d | 5.1 ± 2.7c,d | 7.2 ± 5.4c,d | <0.001* |
| Day 18 | 11.2 ± 6.3a,b,c | 7.6 ± 4.8a,b,d | 4.9 ± 3.7c,d | 5.9 ± 4.2c,d | <0.002* |
| Day 19 | 8.1 ± 3.6a,b,c | 6.3 ± 8.5a,b,d | 3.7 ± 5.6c,d | 4.4 ± 4.5c,d | <0.002* |
| Day 20 | 5.7 ± 6.5a,b,c | 4.0 ± 8.3a,b,d | 2.4 ± 7.6c,d | 3.3 ± 5.6c,d | <0.001* |
| Day 21 | 2.9 ± 4.4a,b,c | 1.7 ± 6.6a,b,d | 0.5 ± 7.6c,d | 1.0 ± 5.6c,d | <0.001* |
Each value represents mean of 5 values ± SD, *p-value ≤ 0.05 was statistically significant. a Significantly different from oral NTZ at p ≤ 0.05. b Significantly different from G2 and G3 dose treated at p ≤ 0.05. c Significantly different from G1 dose at p ≤ 0.05. d Significantly different from Positive Control at p ≤ 0.05.